Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor

NCT01004081 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01004081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
October 31, 2011
Enrollment
54 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer